Coherus Biosciences Inc
CHRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$219.39M
Close$
$-0.30
121.6% downside
Current Fair Value
121.6% downsideOvervalued by 121.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $219.39 Million |
|---|---|
| Enterprise Value | $174.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.95 |
| Outstanding Shares | 154,816,912 |
Return
| Return on Equity | -772.64% |
|---|---|
| Return on Assets | -245.87% |
| Return on Invested Capital | -139.20% |
Valuation & Multiples
| P/E Ratio | -1.39 |
|---|---|
| PEG | 1.3 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.42 |
| Enterprise Value to EBIT | -1.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$14.41 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$15.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.7104▼ 14.87% |
|---|---|
| Total Calls | 29,700▼ 41.88% |
| Total Puts | 139,900▼ 43.66% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 52.46%▼ 6.99% |
|---|---|
| Total Invested | $101.64M▼ 15.86% |
| Investors Holding | 151▼ 11.00% |
ESG Score
No data
About Coherus Biosciences Inc
CEO: Dennis Lanfear